LOGIN 

 

JOIN

 

RENEW

2019 Press Releases

HomeAboutNewsroomPress ReleasesPress Releases from the ATS2019 Press Releases ▶ ATS Foundation/Mallinckrodt Pharmaceuticals Research Fellowship in Sarcoidosis Awarded; Ohio State University Researcher is Recipient of $80,000 Grant
ATS Foundation/Mallinckrodt Pharmaceuticals Research Fellowship in Sarcoidosis Awarded; Ohio State University Researcher is Recipient of $80,000 Grant

(New York, NY) – April 4, 2019 – Landon W. Locke, PhD, of Ohio State University has been awarded the ATS Foundation/Mallinckrodt Pharmaceuticals Research Fellowship in Sarcoidosis. The $80,000 award will help fund Dr. Locke’s study, “Abnormally Sustained M2-like Macrophage Polarization Drives Sarcoidosis Granulomas.”

Sarcoidosis is a chronic granulomatous inflammatory disease. It occurs in about 15 to 40 per 100,000 people in the U.S., with a disproportionately higher rate observed in people of African-American and Northern European descent. Approximately one-third of patients have a progressive form of the disease characterized by chronic, unremitting inflammation in multiple organ systems.

“This grant, a partnership between the ATS Foundation and Mallinckrodt, will provide critical resources to investigators working to improve the lives of our patients,” noted Eric White, MD, MS, director of Translational Interstitial Lung Disease Research in the Division of Pulmonary and Critical Care Medicine at the University of Michigan Medical School and past chair of the ATS Scientific Advisory Commitee, upon the announcement of the research fellowship in 2018.

“We at Mallinckrodt are pleased to continue our support of this sarcoidosis research fellowship, expanding on the important discovery work undertaken to facilitate insights that may benefit health care providers and patients living with this rare disease,” said Tunde Otulana, MD, senior vice president and chief medical officer of Mallinckrodt. "We are proud supporters of the ATS Foundation and its exemplary commitment to research, and excited by the potential of Dr. Locke’s study. Collaborations such as these are vital to scientific advances.”

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Learn more about the ATS Foundation/Mallinckrodt Pharmaceuticals Research Fellowship, and additional fellowship opportunities on our website.